Sierra Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sierra Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-502	Closed	-$39K	–	738
2022 Q1	$39K	Hold	502	–	–	0.01%	368
2021 Q4	$44K	Hold	502	–	–	0.01%	354
2021 Q3	$39K	Hold	502	–	–	0.01%	319
2021 Q2	$42K	Hold	502	–	–	0.01%	298
2021 Q1	$38K	Buy	+502	New	+$41K	0.01%	287

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sierra Capital's BMRN Position: Q2 2022 in Review

Sierra Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 502 shares — an estimated $39K sold.

Sierra Capital first reported a position in BMRN in Q1 2021 and held it in 5 quarters. The position peaked at $44K in Q4 2021. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Sierra Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Sierra Capital sold 502 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $39K.
Sierra Capital first reported a position in BioMarin Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Sierra Capital's BioMarin Pharmaceuticals position peaked at $44K in Q4 2021.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Sierra Capital's 13F filing for Q2 2022, filed 4 Aug 2022.